Sort
10,766 grants matching “checkpoint inhibitor”
Targeting STAT3 with Novel Thiomorpholino Antisense Oligonucleotides for Cancer Therapy
$400,000Xuedong Liu · Vesicle Therapeutics Inc. · R41 · FY2025 · CA
An Aptamer-directed IgG1-Fc Drug Conjugate (AFDC) for Treating Pancreatic Cancer
$400,000Xiang Gao · Oncotrap, Inc. · R43 · FY2023 · CA
The immunosuppressive function of Checkpoint kinase 2 in gliomas
$400,000Crismita Clement Dmello · Northwestern University At Chicago · R01 · FY2024 · NS
Development of drug conjugates of R-spondin peptibodies for the treatment of colorectal cancer
$400,000Jie Cui · Wntrix, Inc. · R41 · FY2023 · CA
Optimization of TIL Cell Manufacturing for Cancer Treatment
$400,000Soon Seog Jeong · Human Cell Co · R43 · FY2023 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1
$399,986Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2022 · CA
A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform
$399,979Chun Wang · Trekka Therapeutics, Llc · R41 · FY2023 · CA
PHASE I AWARD - AN ORGAN-ON-VASCULARNET MODEL FOR IN VITRO EVALUATION OF RADIATION AND DRUG THERAPIES
$399,975Claude Rogers · Chromologic, Llc · N43 · FY2024 · CA
Developing engineered inhibitors of tRNA modifying enzymes
$399,966Austin Stratton Draycott · Cloverleaf Bio, Inc. · R42 · FY2025 · CA
CD3 bispecific for the treatment of ROR2-positive NSCLC
$399,955Jean-Loup Romet-Lemonne · Traverse Biotech Ii Inc · R43 · FY2023 · CA
Automated plasma EV-PDL1 analysis for cancer immunotherapy
$399,913Liyun Jessica Sang · Accure Health, Inc. · R43 · FY2022 · CA
Development of a salt-based nanomedicine for non-muscle invasive bladder cancer
$399,907Zhi Liu · Athna Biotech, Inc. · R43 · FY2022 · CA
Human specific STING agonists for the treatment of cancer
$399,812Glen N Barber · Stinginn, Llc · R41 · FY2023 · CA
Project 1: Glutaminolytic GDH1 activation-dependent immunotherapy resistance in LKB1-mutant lung adenocarcinoma
$399,749Sumin Kang · Emory University · P01 · FY2024 · CA
Targeting DYRK2 to eradicate leukemia stem cells in chronic myeloid leukemia.
$399,746H. Daniel Lacorazza · Baylor College Of Medicine · R01 · FY2025 · CA
Engineering a potent locally-acting interleukin 12-expressing synthetic self-replicating mRNA to augment responses to anti-PD-1 therapy in neoadjuvant triple negative breast cancer
$399,725Tasuku Kitada · Strand Therapeutics Inc · R43 · FY2021 · CA
PLA2G2D Antibodies for Cancer Immunotherapy
$399,618Li-Fen Lee · Apeximmune Therapeutics Inc. · R43 · FY2023 · CA
Development of Lasso Peptides as Potent Endothelin Receptor B Antagonists for Immuno-oncology
$399,609Mark J Burk · Lassogen, Inc. · R43 · FY2021 · CA
An innovative telomerase-targeted, circulating tumor cell assay for monitoring NSCLC treated with radiation and immunotherapy
$399,499Deeksha Saxena · Liquid Biodx Llc · R43 · FY2023 · CA
A novel targeted antibody therapeutic to treat ovarian cancer
$399,478Reiner Laus · Trio Pharmaceuticals Inc. · R43 · FY2024 · CA
Novel Anti-CCR8 VHH for the Treatment of NSCLC
$399,424Mauro Mileni · Abilita Bio, Inc. · R43 · FY2023 · CA
ST8Sia6 expression on tumors inhibits the immune response
$399,403Virginia Smith Shapiro · Mayo Clinic Rochester · R01 · FY2021 · CA
The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy
$399,379Benjamin Izar · Columbia University Health Sciences · R01 · FY2023 · CA
Effects of ATR-CHK1 inhibition on genome stability and cancer progression
$399,329Eric J Brown · University Of Pennsylvania · R01 · FY2016 · CA
Effects of ATR-CHK1 inhibition on genome stability and cancer progression
$399,329Eric J Brown · University Of Pennsylvania · R01 · FY2017 · CA